Amgen And Allergan Announce Positive Top-line Results From Phase 3 Study of Biosimilar Candidate ABP 215 Read more about Amgen And Allergan Announce Positive Top-line Results From Phase 3 Study of Biosimilar Candidate ABP 215
FDA Grants Priority Review for Amgen's Supplemental New Drug Application for Expanded Labeling of Kyprolis® (Carfilzomib) in Relapsed Multiple Myeloma Read more about FDA Grants Priority Review for Amgen's Supplemental New Drug Application for Expanded Labeling of Kyprolis® (Carfilzomib) in Relapsed Multiple Myeloma
Amgen To Acquire Privately-Held Dezima Pharma Read more about Amgen To Acquire Privately-Held Dezima Pharma
Amgen And Xencor Announce Strategic Collaboration In Cancer Immunotherapy And Inflammation Read more about Amgen And Xencor Announce Strategic Collaboration In Cancer Immunotherapy And Inflammation
Amgen To Present At The Bank Of America Merrill Lynch Global Healthcare Conference Read more about Amgen To Present At The Bank Of America Merrill Lynch Global Healthcare Conference
Amgen Highlights Key Clinical Data To Be Presented At European Cancer Congress 2015 Read more about Amgen Highlights Key Clinical Data To Be Presented At European Cancer Congress 2015
Amgen To Present At The Morgan Stanley Global Healthcare Conference Read more about Amgen To Present At The Morgan Stanley Global Healthcare Conference
Amgen Submits Application To FDA For New Delivery Option For Monthly Administration Of Repatha™ (Evolocumab) Read more about Amgen Submits Application To FDA For New Delivery Option For Monthly Administration Of Repatha™ (Evolocumab)
Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency Read more about Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency
Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs Read more about Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs
